Please login to the form below

Not currently logged in

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Biopharma looks to genome editing platform to discover hepatitis B cure


Following its success in curing hepatitis C with therapies such as Sovaldi and Harvoni, Gilead is now enlisting a new partner in the fight against hepatitis B (HBV).

Inking a collaboration deal that would be worth half a billion dollars with genome editing specialists Precision Biosciences, Gilead is aiming to develop a cure for HBV, which is proving more difficult to eliminate than hep C.

Current HBV therapies, including Gilead’s own Hepsera, Viread and Vemlidy, focuses on inhibiting viral DNA replication but don't completely clear the virus.

People living with hepatitis B are often on treatments for life, as the presence of covalently closed circular DNA (cccDNA) enables HBV replication if treatment is stopped.

This collaboration however, will target the in vivo elimination of the virus and will use Precision BioSciences’ genome editing platform ARCUS to further develop this goal.

Precision’s chief scientific officer, Derek Jantz commented: "Gilead's cure-based approach to hepatitis B is comprehensive and exciting. Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program.

“This is an excellent application for our technology, which has made notable progress toward therapeutic in vivo editing in relevant models over the last year."

The ARCUS platform is based on a natural genome-editing enzyme homing endonucleases, which identifies long DNA sequences.  These enzymes can modify the genome with a new DNA sequence.

Precisions’ technology however comes from the ARC nuclease, a synthetic enzyme similar to the homing endonuclease. The advantage is that the synthetic enzyme can be customised to recognise a DNA sequence within any target gene.

Gilead's newly appointed R&D Head and chief scientific officer John McHutchison has said the technology has some exciting potential, demonstrating promising in vitro activity.

He said: “Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection.

“We look forward to exploring this [Precision BioScience’s genome editing] technology as an important component of our HBV cure research efforts.”

The deal will see Precision responsible for the development, formulation and preclinical evaluation of the investigational nucleases, while Gilead will clinically develop the candidates and commercialise potential therapies

Precision Bioscience is eligible to receive milestone payments of up to $445m, along with royalties that go up to the mid-teens on sales and commercial products developed through the collaboration.

Gilead needs to find new drugs to replace the revenue lost from its hepatitis C franchise, which proved to be an enormous blockbuster success for a few years, but is now in steep decline. The company had some good news from the field of rheumatoid arthritis earlier this week, but is still looking for a market-leading innovative drug.

Article by
Gemma Jones

14th September 2018

From: Research, Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...